Blood products

China Resources Boya Bio-pharmaceutical Group has issued a stark profit warning for 2025, forecasting net profit attributable to shareholders at RMB105 million to RMB136.5 million—down sharply from

China Resources Boya Bio-pharmaceutical, a major player in blood products and medical aesthetics, has issued a stark profit warning for 2025, forecasting net profit attributable to shareholders at